EPISODE · Jul 7, 2025 · 21 MIN
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
from BiotechTV - News · host BiotechTV
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the need for an oral therapy and the company's commercial strategy now that the approval is in hand.
Embed this episode
Ready to play
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
0:00
21:58
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 21 minutes long.
When was this BiotechTV - News episode published?
This episode was published on July 7, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!